Background: Hemodynamic and hemostatic abnormalities are reportedly frequent in chronic obstructive pulmonary disease (COPD). Objectives: We investigated the changes in systolic pulmonary artery pressure (PAPs) and hemostatic status and the effects of systemic steroid treatment (SST) during COPD exacerbation. Methods: Consecutive 26 male and 4 female patients as well as 10 controls were enrolled. The nonsteroid treatment (NST) group received standard treatment without steroids, and the other group received additional SST. Initial values of blood gases, spirometry and PAPs, P-selectin, D-dimer and fibrinogen levels, activities of thrombocyte aggregation, antithrombin III (AT III), protein C (PC), protein S, activated PC resistance (APCR), prothrombin time and partial thromboplastin time were obtained and compared with values at day 10. Results: Improvement in spirometry and blood gases was more prominent with SST. At presentation, patients had higher PAPs, P-selectin, D-dimer and fibrinogen but lower AT III levels than controls. PAPs and fibrinogen levels significantly decreased in the SST group while P-selectin levels further increased in the NST group. The D-dimer level significantly decreased in both groups. Means of AT III, PC and protein S increased in the SST and decreased in the NST group, but only the decrease in PC in the NST group was meaningful. Compared with the controls, AT III levels in the NST group and activated PC resistance in the SST group were significantly decreased. Thrombocyte aggregation tests suggested an incline after 10 days in both groups. Conclusions: We suggest that in patients with COPD exacerbation, addition of systemic corticosteroids to treatment results in better outcome in normalization of PAPs, hemostasis, pulmonary functions and blood gases.

Keywords:
Chronic obstructive pulmonary disease, Hemostasis, Hemodynamics, Corticosteroids
1.
Hurd S: The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000;117:1s–4s.
2.
Onder I, Topcu S, Dokmetas HS, Turkay C, Seyfikli Z: Platelet aggregation size and volume in chronic obstructive pulmonary disease. Mater Med Pol 1997;29:11–13.
3.
Ashitani J, Mukae H, Arimura Y, Matsukura S: Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med 2002;41:181–185.
4.
Rostagno C, Prisco D, Boddi M, Poggesi L: Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Eur Respir J 1991;4:147–151.
5.
Erelel M, Cuhadaroglu C, Ece T, Arseven O: The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2002;96:515–518.
6.
Hartmann IJC, Hagen PJ, Melissant CF, Postmus PE, Prins MH, on behalf of the Antelope Study Group: Diagnosing acute pulmonary embolism. Am J Respir Crit Care Med 2000;162:2232–2237.
7.
Gottschalk A, Stein PD, Henry JV: Patient stratification by cardiopulmonary status in the diagnosis of pulmonary embolism. J Nucl Med 1996;37:570–572.
8.
Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256–1276.
9.
Cheitlin MD, Armstrong WF, Aurigemma GP, et al: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 2003;42:954–970.
10.
Confalonieri M, Gazzaniga PC, Della Porta R, Gandola L, Aiolfi S, Frisinghelli A, Bellone A: Haemodynamic response during initiation of noninvasive positive pressure ventilation in COPD patients with acute ventilatory failure. Respir Med 1998;92:331–337.
11.
Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, et al: Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189–194.
12.
Camilli AE, Robbins DR, Lebowitz MD: Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991;133:795–800.
13.
Zielinski J, MacNee W, Wedzicha J, Ambrosino N, Braghiroli A, Dolensky J, et al: Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997;52:43–47.
14.
Goldhaber SZ, Simons GR, Elliot CG, et al: Quantitative plasma D-dimer levels among patients undergoing pulmonary angiography for suspected pulmonary embolism. JAMA 1993;270:2819.
15.
Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Cordova C: Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic obstructive bronchitis and haemostasis group. Thromb Haemost 1994;72:343–346.
16.
Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW: Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210–215.
17.
Park CS, Chung SW, Ki SY, Lim GI, Uh ST, Kim YH, Choi DI, Pa JS, Lee DW, Kitaichi M: Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. Am J Respir Crit Care Med 2000;162:1162–1168.
18.
Martin LD, Rochelle LG, Fischer BM, Krunkovsky TM, Adler KB: Airway epithelium as an effector of inflammation: molecular regulation of secondary mediators. Eur Respir J 1997;10:2139–2146.
19.
Gobay C, Kushner I: Acute phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–454.
20.
Rothwell M, Rampling MW, Cholerton S, Sever PS: Haemorheological changes in the short term after abstention from tobacco by cigarette smokers. Br J Haematol 1991;79:500–503.
21.
Morten D, Anne TH, Jorgen V, Peter L, Borge GN: Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1008–1011.
22.
Mennen LI, Balkau B, Charles MA, D’Hour A, le Mauff JM: Gender differences in the relation between fibrinogen, tissue-type plasminogen activator antigen and markers of insulin resistance: effects of smoking. DESIR Study Group. Thromb Haemost 1999;82:1106–1111.
23.
Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Murohara T, Imaizumi T: Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol 2005;45:1280–1286.
24.
Tailor A, Cooper D, Granger DN: Platelet-vessel wall interactions in the microcirculation. Microcirculation 2005;12:275–285.
25.
Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY: Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med 2005;37:61–66.
26.
Cella G, Sbarai A, Mazzaro G, Vanzo B, Romano S, Hoppensteadt T, Fareed J: Plasma markers of endothelial dysfunction in chronic obstructive pulmonary disease. Clin Appl Thromb Hemost 2001;7:205–208.
27.
Ferroni P, Basili S, Martini F, Vieri M, Labbadia G, Cordova C, Alessandri C, Gazzaniga PP, Basil S: Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. J Investig Med 2000;48:211–217.
28.
Nenci GG, Berrettini M, Todisco T, Costantini V, Parise P: Effects of dipyridamole on the hypoxemic pulmonary hypertension of patients with chronic obstructive pulmonary disease. Respiration 1988;53:13–19.
29.
Ashitani J, Mukae H, Arimura Y, Matsukura S: Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med 2002;41:181–185.
30.
Kaminskaia GO, Serebrianaia BA, Kazakova LV: Status of the hemostatic system in patients with chronic lung diseases. Probl Tuberk 1991;8:5–8.
31.
Angelov A, Zekov C: Thrombotic complications originating in the lung in chronic respiratory insufficiency. Z Erkr Atmungsorgane 1984;162:256–261.
32.
Gazzaniga PP, Basili S, Ferroni P, Pulcinelli FM, Pettirossi G, La Mancusa R, Alessandri C, Cordova C: Chronic obstructive pulmonary disease. A possible correlation between platelet aggregation tests and respiratory indexes. ECOB Group. Clin Ter 1993;142:507–516.
33.
Rostagno C, Prisco D, Boddi M, Poggesi L: Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Eur Respir J 1991;4:147–151.
34.
Pandit HB, Spillert CR: Effect of methylprednisolone on coagulation. J Natl Med Assoc 1999;91:453–456.
35.
Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM: Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome. J Endocrinol Invest 2000;23:145–150.
36.
Sin DD, Man SF: Why are patients with COPD at increased risk of cardiovascular disease? The potential role of systemic inflammation in COPD. Circulation 2003;107:1514–1519.
37.
Gan WQ, Man SF, Senthilselvan A, Sin DD: The association between COPD and systemic inflammation: a systematic review and a metaanlysis. Thorax 2004;59:574–580.
38.
Sin D, Lacy P, York E, Man SFP: Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760–765.
39.
Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC: The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592–1596.
40.
Confalonieri M, Mainardi E, Della Porta R, Bernorio S, Gandola L, Beghe B, Spanevello A: Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583–585.
41.
Davies L, Angus RM, Calverley PM: Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999;354:456–460.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.